US 12,220,411 B1
Application of PTGDS inhibitor in preparation of drug for treating cataracts
Jin Li, Wenzhou (CN); Jiasheng Liu, Wenzhou (CN); Yitong Xu, Wenzhou (CN); Mengchao Zhu, Wenzhou (CN); and Haisen Sun, Wenzhou (CN)
Assigned to THE EYE HOSPITAL OF WENZHOU MEDICAL UNIVERSITY, Wenzhou (CN)
Appl. No. 18/692,452
Filed by THE EYE HOSPITAL OR WENZHOU MEDICAL UNIVERSITY, Wenzhou (CN)
PCT Filed Oct. 8, 2023, PCT No. PCT/CN2023/123329
§ 371(c)(1), (2) Date Mar. 15, 2024,
.
Claims priority of application No. 202310914152.1 (CN), filed on Jul. 25, 2023.
Int. Cl. A61K 31/454 (2006.01); A61P 27/12 (2006.01)
CPC A61K 31/454 (2013.01) [A61P 27/12 (2018.01)] 2 Claims
 
1. A method for treating age-related cataracts comprising administering 7-10 UM of the prostaglandin D synthase (PTGDS) inhibitor 4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-[4-(2H-tetrazol-5-yl) butyl]-piperidine (AT-56).